Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Catherine Tsien Swick

Advertisement

Articles by Catherine Tsien Swick

More Effort Needed to Understand Value Breadth of Molecular Testing

ByCatherine Tsien Swick,Lori C. Brisbin
May 6th 2015

As the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.

Advertisement

Latest Updated Articles

  • More Effort Needed to Understand Value Breadth of Molecular Testing
    More Effort Needed to Understand Value Breadth of Molecular Testing

    May 6th 2015



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

2

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

3

Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles

4

Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS

5

Dr Cuglievan on Results for Revumenib in Pediatric R/R KMT2A+ Acute Leukemia

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us